Summary
Definition
History and exam
Key diagnostic factors
- excessive worry for at least 6 months
- anxiety not confined to another mental health disorder
- anxiety not due to medication or substance
- muscle tension
- sleep disturbance
- fatigue
- restlessness
- irritability
- poor concentration
Other diagnostic factors
- headache
- sweating
- dizziness
- gastrointestinal symptoms
- muscle aches
- increased heart rate
- shortness of breath
- trembling
- exaggerated startle response
- chest pain
Risk factors
- family history of anxiety
- physical or emotional stress
- history of physical, sexual, or emotional trauma
- other anxiety disorder
- chronic physical health condition
- female sex
Diagnostic tests
1st tests to order
- clinical diagnosis
Tests to consider
- thyroid function tests
- urine drug screen
- 24-hour urine test for catecholamines, metanephrines, normetanephrines, and creatinine
- pulmonary function tests
- ECG
Treatment algorithm
anxiety symptoms meeting DSM-5-TR criteria
anxiety symptoms not meeting DSM-5-TR criteria
Contributors
Authors
Philip John Cowen, MD, FRCPsych, FMedSci
Professor of Psychopharmacology
Department of Psychiatry
University of Oxford
Oxford
UK
Disclosures
PJC declares that he has no competing interests.
Acknowledgements
Professor Philip John Cowen would like to gratefully acknowledge Dr Christopher Gale, Dr Richard P. Swinson, Dr Elizabeth Hoge, and Dr Phebe Tucker, previous contributors to this topic.
Disclosures
CG is an author of the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline on social phobia, panic disorder, and generalized anxiety disorder. Otago University has commercial and research relationships with multiple pharmaceutical companies. He is an author of a number of references cited in this topic. RPS has personally received royalties for articles published in UpToDate (Wolters Kluwer) and the Compendium of Therapeutic Choices, 2nd edition (Canadian Pharmacists Association). EH is an author of a number of references cited in this topic. PT has conducted research for GlaxoSmithKline, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Astra-Zeneca, Cephalon, Inc., and Ortho-McNeil. She has also consulted for Forest Pharmaceuticals and received honoraria from Pfizer, Inc. and Forest Pharmaceuticals.
Peer reviewers
Lori Davis, MD
Research Director
University of Alabama
School of Medicine Tuscaloosa Campus
College of Community Health Sciences
Tuscaloosa
AL
Disclosures
LD declares that she has no competing interests.
Arianna Di Florio, MD, PhD
Senior Clinical Lecturer
Division of Psychological Medicine and Clinical Neurosciences
Cardiff University
United Kingdom
Disclosures
ADF declares that she has no competing interests.
Elaine Lockhart, MB, BCH, BAO
Consultant in Paediatric Liaison Psychiatry
Royal Hospital for Children
Glasgow
United Kingdom
Divulgaciones
EL declares that she has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014 May;28(5):403-39. Resumen
Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1107-24.Texto completo Resumen
National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Jun 2020 [internet publication].Texto completo
Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
Más DiferencialesGuías de práctica clínica
- Identification and treatment of perinatal mood and anxiety disorders
- Treatment and management of mental health conditions during pregnancy and postpartum
Más Guías de práctica clínicaFolletos para el paciente
Anxiety: what is it?
Anxiety: what are the treatment options?
Más Folletos para el pacienteCalculadoras
GAD-7 Generalized Anxiety Disorder Scale
Más CalculadorasInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad